Teva Agrees To $420m Securities Settlement For Alleged Price Fixing
Israeli Firm Denies Wrongdoing; Proposed Settlement Requires Final Approval
Denying any wrongdoing or admission of liability, Teva has agreed to a proposed settlement of $420m with a class of investors following allegations that the firm had concealed the true nature of its increase in profits, which artificially inflated the price of Teva’s securities.
